SHIN-MEI WONGChiang, Bing JuinBing JuinChiangChen, Hui ChunHui ChunChenWu, Yi NoYi NoWuLin, Ying HungYing HungLinLiao, Chun HouChun HouLiao2023-08-312023-08-312021-10-0118795226https://scholars.lib.ntu.edu.tw/handle/123456789/634841Purpose: The objective of this study was to investigate the safety and efficacy of intracavernosal platelet-rich plasma (PRP) injection in patients with erectile dysfunction (ED). Materials and Methods: Between September 2018 and September 2020, thirty participants with ED were enrolled in this prospective single-Arm study. All participants received three sessions of intracavernosal PRP injection. Oral phosphodiesterase type 5 (PDE5) inhibitors or testosterone replacement therapy (TRT) without a change in dosing was permitted during the treatment period. Efficacy was assessed using the International Index of Erectile Function-5 (IIEF-5), Erectile Hardness Score (EHS), Sexual Encounter Profile (SEP) 2 and 3, and Global Assessment Question, every 2 weeks after each treatment session. Any adverse events were recorded. Results: The mean age of participants was 54.93 years. Oral PDE5 inhibitors were prescribed to 76.7% of participants (n = 23), and 50% of participants (n = 15) received concurrent TRT. A significant improvement in erectile function was measured by an average of 4.556 points in IIEF-5 (P < 0.001) and 0.72 points in EHS (P < 0.001). In total, 4 (13.3%) and 15 (50%) participants reported 'no' to 'yes' in SEP2 and SEP3 questions after therapy, respectively. Overall, 82.8% of participants agreed that the study therapy improved erectile function. No significant adverse events were reported. Conclusion: This single-Arm prospective study revealed that preliminary experience with penile PRP significantly improves erectile function without obvious adverse events.Erectile dysfunction | intracavernous platelet-rich plasma | platelet-rich plasmajournal article10.4103/UROS.UROS_22_212-s2.0-85121904882https://api.elsevier.com/content/abstract/scopus_id/85121904882